Brave Asset Management’s Novo Nordisk NVO Stock Holding History

Brave Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,896	Closed	-$216K	–	176
2025 Q3	$216K	Buy	+3,896	New	+$228K	0.05%	138
2016 Q4	–	Sell	-1,000	Closed	-$21K	–	267
2016 Q3	$21K	Hold	1,000	–	–	0.01%	281
2016 Q2	$27K	Hold	1,000	–	–	0.02%	270
2016 Q1	$27K	Hold	1,000	–	–	0.02%	269
2015 Q4	$29K	Hold	1,000	–	–	0.02%	269
2015 Q3	$27K	Hold	1,000	–	–	0.02%	263
2015 Q2	$27K	Hold	1,000	–	–	0.02%	288
2015 Q1	$27K	Hold	1,000	–	–	0.02%	285
2014 Q4	$21K	Hold	1,000	–	–	0.02%	310
2014 Q3	$24K	Hold	1,000	–	–	0.02%	287
2014 Q2	$23K	Hold	1,000	–	–	0.02%	290
2014 Q1	$23K	Hold	1,000	–	–	0.02%	286
2013 Q4	$18K	Buy	+1,000	New	+$17.4K	0.01%	301

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brave Asset Management's NVO Position: Q4 2025 in Review

Brave Asset Management sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,896 shares — an estimated $216K sold.

Brave Asset Management first reported a position in NVO in Q4 2013 and held it in 13 quarters. The position peaked at $216K in Q3 2025. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Brave Asset Management reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Brave Asset Management sold 3,896 Novo Nordisk shares in Q4 2025, an estimated $216K.
Brave Asset Management first reported a position in Novo Nordisk in Q4 2013 and held it in 13 quarters.
Brave Asset Management's Novo Nordisk position peaked at $216K in Q3 2025.
1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Brave Asset Management's 13F filing for Q4 2025, filed 8 Jan 2026.